[Comment] NOR-TEST-ing tenecteplase in acute ischaemic stroke

Despite the transformational impact of endovascular treatment on patients with acute ischaemic stroke from proximal cerebral artery occlusion, thrombolysis with intravenous alteplase remains the mainstay of reperfusion therapy because it is widely available and the standard of care upon which the evidence for endovascular treatment has been based.1 However, because alteplase has well recognised limitations, including reduced efficacy in large clots, risk of major intracranial haemorrhage, and requirement for a continuous infusion, there is an imperative to continue efforts to find more efficient, more effective, and safer lytic treatment in acute ischaemic stroke.
Source: Lancet Neurology - Category: Neurology Authors: Tags: Comment Source Type: research